Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,196 matching trials from the live ClinicalTrials.gov search.

Filters: Durham, North Carolina Clear all

Conditions: Sarcoma
Interventions: trabectedin; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 32
States / cities: Los Angeles, California • Hartford, Connecticut • New Britain, Connecticut + 25 more

Conditions: Liver Diseases
Interventions: Uncertainty Management Intervention, Comparison Conditions for Liver Transplant; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: Omaha, Nebraska • Chapel Hill, North Carolina • Durham, North Carolina + 1 more

Conditions: HIV Infections, AIDS-Related Opportunistic Infections
Interventions: Emtricitabine/tenofovir disoproxil fumarate, Lopinavir/ritonavir, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 43
States / cities: Sacramento, California • San Diego, California • San Francisco, California + 24 more

Conditions: Graft Versus Host Disease
Interventions: cyclosporine, hydroxychloroquine, prednisone, tacrolimus; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 29 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 89
States / cities: Tucson, Arizona • Little Rock, Arkansas • Downey, California + 67 more

Conditions: Thoracic Aortic Aneurysm
Interventions: Endovascular repair, Surgical; Device · Procedure
Lead sponsor: Cook Group Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 38
States / cities: Mesa, Arizona • Phoenix, Arizona • San Francisco, California + 28 more

Conditions: Pancreatic Adenocarcinoma
Interventions: Gemzar (Gemcitabine), TH-302; Drug
Lead sponsor: ImmunoGenesis; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 59
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 52 more

Conditions: HIV Infections
Interventions: Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 66
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 42 more

Conditions: Lung Cancer
Interventions: 6-hydroxymethylacylfulvene; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 48
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more

Conditions: Ovarian Clear Cell Cystadenocarcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions: Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Paclitaxel, Temsirolimus; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 121
States / cities: Phoenix, Arizona • Burbank, California • Los Angeles, California + 82 more

Conditions: Lymphedema, Perioperative/Postoperative Complications, Vulvar Cancer
Interventions: fibrin sealant, surgical wound closure; Drug · Procedure
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 45 more

Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Interventions: The Cleerly CAD Staging System; Device
Lead sponsor: Cleerly, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 7,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 125
States / cities: Chandler, Arizona • Scottsdale, Arizona • Sun City, Arizona + 100 more

Conditions: Diabetes Mellitus, Type 2
Interventions: AC2993, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 129
States / cities: Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more

Conditions: Cervical Degenerative Disc Disease
Interventions: Cervical TDR, ACDF with plate; Device
Lead sponsor: DePuy Spine; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 30
States / cities: Beverly Hills, California • Sacramento, California • Loveland, Colorado + 26 more

Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Interventions: Guadecitabine, Treatment Choice; Drug · Other
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 22
States / cities: Duarte, California • Rancho Mirage, California • Fleming Island, Florida + 18 more

Conditions: Lung Cancer
Interventions: cetuximab, carboplatin, pemetrexed disodium, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 71
States / cities: Arroyo Grande, California • Castro Valley, California • Hayward, California + 56 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Obinutuzumab, Quality-of-Life Assessment, Venetoclax; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 69 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 864
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 552 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 1,629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 109
States / cities: Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 83 more

Conditions: Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions: XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,002 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Matching placebo to Seltorexant, Quetiapine XR, Matching placebo to Quetiapine XR; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 757 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 75
States / cities: Birmingham, Alabama • Tucson, Arizona • Culver City, California + 62 more

Conditions: Advanced Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Merkel Cell Carcinoma, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions: Pembrolizumab, Stereotactic Body Radiation Therapy; Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 254
States / cities: Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 172 more

Conditions: Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder
Interventions: Armodafinil 100 to 250 mg/day; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 64 more

Conditions: Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Pulmonary Embolism, Splanchnic Vein Thrombosis
Interventions: Apixaban; Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 32
States / cities: Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 27 more

Conditions: Lung Cancer
Interventions: carboplatin, gemcitabine hydrochloride, paclitaxel, radiation therapy; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 74
States / cities: Anniston, Alabama • La Jolla, California • Los Angeles, California + 55 more

Conditions: Diffuse Large-Cell Lymphoma
Interventions: CPOP-R, CHOP-R; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 58
States / cities: Concord, California • Hollister, California • La Jolla, California + 51 more

Search by objective public record fields.

Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus

Uncertainty Management Intervention

When to Start Anti-HIV Drugs in Patients With Opportunistic Infections

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

STARZ-TX2 Clinical Study: Study of Thoracic Aortic Aneurysm Repair With the Zenith TX2 Endovascular Graft

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex

Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Comparison of DISCOVER™ Artificial Cervical Disc and ACDF for Treatment of Cervical DDD (IDE Study)

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin